If you're considering compounded semaglutide through PlexusDx, discussing your genetic predispositions with your provider can support a more informed conversation about starting dose, expected titration timeline, and whether a dual-agonist approach might be preferable
This is a significant advantage considering that individuals with this condition are often at a higher risk for these events
It is important to understand why those products are different from what you receive through a clinic like ours
People were fighting back and forth about this for a long time, until TECOS, the trial with sitagliptin which was the largest and the best of those trials came out with a completely flat result: there was neither an increase nor a decrease in cardiovascular risk
The rest of the parameters were set as the default, which included precursor FDR set to 1% and peptide length of 730 amino acids
But, like with any medication taken for years, there are still some unknowns